Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
M.D. Anderson Cancer Center
Hoffmann-La Roche
Hoffmann-La Roche
Charite University, Berlin, Germany
Amgen
Hoffmann-La Roche
Ohio State University Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Genentech, Inc.
Fondazione Ricerca Traslazionale
Genentech, Inc.
University of Southern California
ImmunityBio, Inc.
Hoffmann-La Roche
Boehringer Ingelheim
Big Ten Cancer Research Consortium
Technische Universität Dresden
Intergroupe Francophone de Cancerologie Thoracique
Intergroupe Francophone de Cancerologie Thoracique
National Cancer Institute (NCI)
Shanghai Henlius Biotech
ImmunityBio, Inc.
University of California, Irvine
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Exelixis
University College, London
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Fundación GECP
Kahr Medical
Norwegian University of Science and Technology
National Taiwan University Hospital
Galecto Biotech AB
Instituto Oncológico Dr Rosell
NeoImmuneTech